TN2011000307A1 - Galenic formulation of organic compounds - Google Patents
Galenic formulation of organic compoundsInfo
- Publication number
- TN2011000307A1 TN2011000307A1 TN2011000307A TN2011000307A TN2011000307A1 TN 2011000307 A1 TN2011000307 A1 TN 2011000307A1 TN 2011000307 A TN2011000307 A TN 2011000307A TN 2011000307 A TN2011000307 A TN 2011000307A TN 2011000307 A1 TN2011000307 A1 TN 2011000307A1
- Authority
- TN
- Tunisia
- Prior art keywords
- core
- tablet
- organic compounds
- outer coating
- dosage form
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000003826 tablet Substances 0.000 abstract 3
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 abstract 1
- 229960004601 aliskiren Drugs 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000008185 minitablet Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007892 solid unit dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151496 | 2009-01-28 | ||
| PCT/EP2010/050886 WO2010086312A1 (fr) | 2009-01-28 | 2010-01-27 | Formulations galéniques de composés organiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000307A1 true TN2011000307A1 (en) | 2012-12-17 |
Family
ID=40770648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000307A TN2011000307A1 (en) | 2009-01-28 | 2011-06-16 | Galenic formulation of organic compounds |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20110287100A1 (fr) |
| EP (1) | EP2391345B1 (fr) |
| JP (1) | JP2012516299A (fr) |
| KR (1) | KR20110117199A (fr) |
| CN (1) | CN102300558A (fr) |
| AR (1) | AR075179A1 (fr) |
| AU (1) | AU2010209787B2 (fr) |
| BR (1) | BRPI1007452A2 (fr) |
| CA (1) | CA2749531A1 (fr) |
| CL (1) | CL2011001817A1 (fr) |
| CO (1) | CO6400184A2 (fr) |
| EC (1) | ECSP11011289A (fr) |
| ES (1) | ES2525648T3 (fr) |
| IL (1) | IL213918A0 (fr) |
| MA (1) | MA33060B1 (fr) |
| MX (1) | MX2011007779A (fr) |
| MY (1) | MY153852A (fr) |
| NZ (1) | NZ593622A (fr) |
| PE (1) | PE20110943A1 (fr) |
| PL (1) | PL2391345T3 (fr) |
| PT (1) | PT2391345E (fr) |
| RU (1) | RU2535090C2 (fr) |
| SG (1) | SG172226A1 (fr) |
| TN (1) | TN2011000307A1 (fr) |
| TW (1) | TWI468191B (fr) |
| WO (1) | WO2010086312A1 (fr) |
| ZA (1) | ZA201104489B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5822758B2 (ja) * | 2011-03-02 | 2015-11-24 | 第一三共ヘルスケア株式会社 | 速溶性防湿フィルムコーティング製剤及びその製造方法 |
| EP2596802A1 (fr) * | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Composition pharmaceutique pour le traitement des réactions allergiques |
| JP6810152B2 (ja) | 2016-02-03 | 2021-01-06 | ノバルティス アーゲー | サクビトリルおよびバルサルタンの組合せの新規使用 |
| JP7461295B2 (ja) * | 2018-08-10 | 2024-04-03 | キッセイ薬品工業株式会社 | スクロオキシ水酸化鉄含有顆粒及び医薬組成物 |
| WO2020169991A1 (fr) * | 2019-02-22 | 2020-08-27 | Catalent U.K. Swindon Zydis Limited | Préservation de particules d'api à revêtement fonctionnel produites par des procédés de mélange sans solvant dans une suspension aqueuse |
| CN113453662A (zh) | 2019-02-22 | 2021-09-28 | 康特伦英国斯温顿捷迪斯有限公司 | 储存期间药物颗粒包衣材料的团聚最小化以稳定化药物产品的崩解时间 |
| GB2585412B (en) | 2019-02-22 | 2023-10-04 | Catalent Uk Swindon Zydis Ltd | Minimizing aeration of suspensions during in-line mixing |
| US11166919B2 (en) | 2019-02-22 | 2021-11-09 | Catalent U.K. Swindon Zydis Limited | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen |
| WO2021011538A1 (fr) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation |
| IL300129A (en) | 2020-07-31 | 2023-03-01 | Catalent Uk Swindon Zydis Ltd | Pharmaceutical preparations containing a coated API |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| AU2022253899A1 (en) | 2021-04-07 | 2023-10-26 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (fr) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides |
| WO2025105451A1 (fr) * | 2023-11-17 | 2025-05-22 | 第一三共ヘルスケア株式会社 | Préparation solide |
| WO2025122954A1 (fr) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| WO2004100871A2 (fr) * | 2003-05-09 | 2004-11-25 | Pharmacia Corporation | Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine |
| MY144477A (en) | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| BRPI0509971A (pt) * | 2004-04-15 | 2007-10-02 | Reddys Lab Inc Dr | uma forma de dosagem farmacêutica, comprimido e método de preparação |
| ATE551052T1 (de) * | 2004-10-08 | 2012-04-15 | Novartis Ag | Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz |
| RU2010116526A (ru) * | 2007-09-28 | 2011-11-10 | Новартис АГ (CH) | Фармацевтическая комбинация алискирена и валсартана |
-
2010
- 2010-01-27 MA MA34114A patent/MA33060B1/fr unknown
- 2010-01-27 RU RU2011135417/15A patent/RU2535090C2/ru not_active IP Right Cessation
- 2010-01-27 JP JP2011546822A patent/JP2012516299A/ja active Pending
- 2010-01-27 CN CN2010800057033A patent/CN102300558A/zh active Pending
- 2010-01-27 SG SG2011044450A patent/SG172226A1/en unknown
- 2010-01-27 ES ES10702092.7T patent/ES2525648T3/es active Active
- 2010-01-27 PT PT107020927T patent/PT2391345E/pt unknown
- 2010-01-27 MY MYPI2011003186A patent/MY153852A/en unknown
- 2010-01-27 KR KR1020117019809A patent/KR20110117199A/ko not_active Ceased
- 2010-01-27 AU AU2010209787A patent/AU2010209787B2/en not_active Ceased
- 2010-01-27 EP EP10702092.7A patent/EP2391345B1/fr not_active Not-in-force
- 2010-01-27 MX MX2011007779A patent/MX2011007779A/es not_active Application Discontinuation
- 2010-01-27 AR ARP100100193A patent/AR075179A1/es unknown
- 2010-01-27 PE PE2011001391A patent/PE20110943A1/es not_active Application Discontinuation
- 2010-01-27 US US13/145,454 patent/US20110287100A1/en not_active Abandoned
- 2010-01-27 TW TW99102290A patent/TWI468191B/zh not_active IP Right Cessation
- 2010-01-27 WO PCT/EP2010/050886 patent/WO2010086312A1/fr not_active Ceased
- 2010-01-27 PL PL10702092T patent/PL2391345T3/pl unknown
- 2010-01-27 CA CA2749531A patent/CA2749531A1/fr not_active Abandoned
- 2010-01-27 BR BRPI1007452A patent/BRPI1007452A2/pt not_active IP Right Cessation
- 2010-01-27 NZ NZ593622A patent/NZ593622A/en not_active IP Right Cessation
-
2011
- 2011-06-16 TN TN2011000307A patent/TN2011000307A1/fr unknown
- 2011-06-17 ZA ZA2011/04489A patent/ZA201104489B/en unknown
- 2011-07-04 IL IL213918A patent/IL213918A0/en unknown
- 2011-07-27 CL CL2011001817A patent/CL2011001817A1/es unknown
- 2011-07-28 CO CO11095153A patent/CO6400184A2/es not_active Application Discontinuation
- 2011-08-26 EC EC2011011289A patent/ECSP11011289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2391345A1 (fr) | 2011-12-07 |
| KR20110117199A (ko) | 2011-10-26 |
| CL2011001817A1 (es) | 2012-01-13 |
| EP2391345B1 (fr) | 2014-09-03 |
| HK1161125A1 (en) | 2012-08-24 |
| CA2749531A1 (fr) | 2010-08-05 |
| SG172226A1 (en) | 2011-07-28 |
| CO6400184A2 (es) | 2012-03-15 |
| MX2011007779A (es) | 2011-08-12 |
| US20110287100A1 (en) | 2011-11-24 |
| ZA201104489B (en) | 2012-02-29 |
| MA33060B1 (fr) | 2012-02-01 |
| AU2010209787A1 (en) | 2011-07-14 |
| MY153852A (en) | 2015-03-31 |
| RU2011135417A (ru) | 2013-03-10 |
| IL213918A0 (en) | 2011-07-31 |
| JP2012516299A (ja) | 2012-07-19 |
| RU2535090C2 (ru) | 2014-12-10 |
| PT2391345E (pt) | 2014-12-03 |
| ECSP11011289A (es) | 2011-09-30 |
| ES2525648T3 (es) | 2014-12-26 |
| BRPI1007452A2 (pt) | 2016-02-16 |
| CN102300558A (zh) | 2011-12-28 |
| AR075179A1 (es) | 2011-03-16 |
| AU2010209787B2 (en) | 2013-06-06 |
| TW201038300A (en) | 2010-11-01 |
| WO2010086312A1 (fr) | 2010-08-05 |
| PL2391345T3 (pl) | 2015-03-31 |
| TWI468191B (zh) | 2015-01-11 |
| PE20110943A1 (es) | 2012-01-22 |
| NZ593622A (en) | 2013-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000307A1 (en) | Galenic formulation of organic compounds | |
| WO2008040534A3 (fr) | Formes pharmaceutiques à base de film non muco-adhésif | |
| MY152279A (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
| NZ589437A (en) | Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| WO2013101897A3 (fr) | Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés | |
| WO2012007159A3 (fr) | Nouvelles formes médicamenteuses à rétention gastrique | |
| WO2009085990A3 (fr) | Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| TN2010000135A1 (en) | Galenical formulations of organic compounds | |
| PH12012502085A1 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| PT2205279E (pt) | Associação farmacêutica de aliscireno e valsartan | |
| ME02474B (fr) | Schémas thérapeutiques | |
| WO2011037976A3 (fr) | Formulations pharmaceutiques de pramipexole | |
| SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
| WO2007145863A3 (fr) | Formulation à libération prolongée de naltréxone | |
| WO2010012459A3 (fr) | Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques | |
| GB2455875B (en) | A process for the preparation of an orally administered unit dose tablet | |
| WO2010044097A3 (fr) | Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci | |
| GB0703674D0 (en) | A Process For The Preparation of an Orally Administered Unit Dose Tablet | |
| PL2291374T3 (pl) | Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej | |
| WO2013098268A3 (fr) | Comprimés et agents enrobés à sec | |
| GB0920721D0 (en) | An orally administered anthelmintic unit dose tablet and process for the preparation thereof | |
| WO2010013925A3 (fr) | Composition pharmacologique destinée à la prévention et au traitement d’une maladie respiratoire, contenant un composé de pyrazolopyrimidinone ou des sels pharmaceutiquement acceptables de celui-ci |